GLPwatch
Trials (2101)
Page 17 of 36.
- Safety, Tolerability and Pharmacokinetics of Intraarticular 4P004 Single Dose in Patient With KL 2-4 Osteoarthritic Knee
- A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years
- Research of Intensive Metabolic Intervention Before Pregnancy in PCOS
- A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients
- Semaglutide and Cognition in Healthy Volunteers
- Semaglutide in Nonalcoholic Fatty Liver Disease
- A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
- Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes
- Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure
- Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.
- The Effect of a Liraglutide on IVF in Obese PCOS
- A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment.
- ECHO for Diabetes and Multiple Chronic Conditions Study
- Impact of Liraglutide on Sensory Perception, Sensory Specific Satiety, Liking and Wanting in Type 2 Diabetic Patients
- Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo
- GLP-1 Analogs for Neuroprotection After Cardiac Arrest
- The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET
- GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis
- Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients
- RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
- A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus
- Effects of Liraglutide on Kidney Function in Type 2 Diabetic Patients
- Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin
- Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
- Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes
- Intravenous Exenatide (Byetta) During Surgery
- A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes
- Effects of Semaglutide in HIV-Associated Lipohypertrophy
- A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia
- Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes
- A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
- Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus
- Observational Study of Interstitial Glucose Monitoring With Continuous Glucose Monitoring to Track Patients Treated With Exenatide
- Genetic, Microbiological and Behavioral Factors in Obesity
- Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)
- A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
- Liraglutide Effects on Epicardial Fat Inflammatory Genes
- Effects of Liraglutide in Chronic Obstructive Pulmonary Disease
- A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus
- Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants
- Role Of Metabolic Adaptation In Weight Regain
- CRAVE Study: Comparing Craving Responses and Diet Quality of GLP1 Receptor Agonist Users
- Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.
- A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
- Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.
- Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA Treatment
- Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes
- The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients
- Weight Loss in Adults Using Semaglutide (Real-world Study)
- A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
- Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics
- Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JY09
- A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects
- A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
- Semaglutide Use in Elderly Obese Patients
- Effect of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Stimulation on Smoking Consumption in Type 2 Diabetes Patients
- Tirzepatide vs Liraglutide in Bone
- A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease
- A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects
- Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder